Company intelligence / Profile preview

Xylogenics

Brownsburg, Indiana, United States

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Xylogenics develops genetically engineered yeast strains to improve fermentation efficiency in fuel ethanol production and other bio-based chemical manufacturing. The company's primary product, GX-1, is designed to increase yields, reduce enzyme costs, and enable faster fermentations in industrial settings.

Modalities: Engineered microorganism
Industry: Non-Drug Biotech

Partnerships

Strategic partnerships in negotiation with multiple industry leaderscollaborations with ethanol production plants for commercial trialing

Beyond the preview

Go deeper on Xylogenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xylogenics.

Explore the full profile